Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 KSI-301 versus aflibercept in wet age-related macular degeneration
2021-000225-27Phase 3Completed
- Sponsor
- Kodiak Sciences
- Start
- Jul 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in exudative macular degeneration comparing KSI-301 arm with Aflibercept arm (2 arms). Primary endpoint: Mean change in best-corrected visual acuity from baseline to Week 40. Started Jul 2021; status: completed.
02
Drugs
tarcocimab tedromeraflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2021-000225-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000225-27.